Neogenomics Stock Analysis

NeoGenomics Stock Analysis Notes

About 100.0% of the company shares are owned by institutional investors. The book value of NeoGenomics was now reported as 7.09. The company has Price/Earnings (P/E) ratio of 272.37. NeoGenomics recorded a loss per share of 0.61. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 16th of April 2003. NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Neogenomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people. To find out more about NeoGenomics contact Christopher BSc at 239 768 0600 or learn more at https://www.neogenomics.com.

NeoGenomics Investment Alerts

NeoGenomics Upcoming and Recent Events

NeoGenomics Largest EPS Surprises

View All Earnings Estimates

NeoGenomics Environmental, Social, and Governance (ESG) Scores

NeoGenomics Stock Institutional Investors

Note, although NeoGenomics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

NeoGenomics Market Capitalization

The company currently falls under 'Mid-Cap' category with a total capitalization of 2.33 B.

NeoGenomics Profitablity

The company has Net Profit Margin of (0.12) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.08) %, which entails that for every $100 of revenue, it lost $0.08.

Management Efficiency

NeoGenomics has Return on Asset of (0.0276) % which means that on every $100 spent on assets, it lost $0.0276. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0838) %, meaning that it generated no profit with money invested by stockholders. NeoGenomics' management efficiency ratios could be used to measure how well NeoGenomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of December 2024, Return On Tangible Assets is likely to drop to -0.12. In addition to that, Return On Capital Employed is likely to grow to -0.06. At this time, NeoGenomics' Fixed Asset Turnover is very stable compared to the past year.

Technical Drivers

As of the 12th of December 2024, NeoGenomics secures the Downside Deviation of 2.51, risk adjusted performance of 0.0807, and Mean Deviation of 1.96. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NeoGenomics, as well as the relationship between them.

NeoGenomics Price Movement Analysis

NeoGenomics Insider Trading Activities

NeoGenomics Outstanding Bonds

NeoGenomics Predictive Daily Indicators

NeoGenomics Corporate Filings

NeoGenomics Forecast Models

NeoGenomics' time-series forecasting models are one of many NeoGenomics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NeoGenomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how NeoGenomics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NeoGenomics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NeoGenomics. By using and applying NeoGenomics Stock analysis, traders can create a robust methodology for identifying NeoGenomics entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. NeoGenomics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. NeoGenomics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

NeoGenomics stock analysis indicators help investors evaluate how NeoGenomics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading NeoGenomics shares will generate the highest return on investment. By understating and applying NeoGenomics stock analysis, traders can identify NeoGenomics position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.